Ginkgo Bioworks Holdings Inc (DNA)
0.4497
-0.01
(-2.66%)
USD |
NYSE |
Jun 14, 16:00
0.4518
0.00 (0.00%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Cash from Investing (Quarterly): -12.11M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -12.11M |
| December 31, 2023 | -46.67M |
| September 30, 2023 | -3.381M |
| June 30, 2023 | -11.22M |
| March 31, 2023 | -19.41M |
| December 31, 2022 | 29.74M |
| September 30, 2022 | -46.49M |
| Date | Value |
|---|---|
| June 30, 2022 | -14.66M |
| March 31, 2022 | -35.98M |
| December 31, 2021 | 4.228M |
| September 30, 2021 | -30.51M |
| June 30, 2021 | -23.93M |
| March 31, 2021 | -23.05M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-46.67M
Minimum
Dec 2023
29.74M
Maximum
Dec 2022
-17.96M
Average
-19.41M
Median
Mar 2023
Cash from Investing (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | -34.14M |
| Teladoc Health Inc | -35.51M |
| Prime Medicine Inc | -37.03M |
| Inovio Pharmaceuticals Inc | 45.38M |
| Nektar Therapeutics | 19.26M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -89.26M |
| Cash from Financing (Quarterly) | -0.845M |
| Free Cash Flow | -322.24M |
| Free Cash Flow Per Share (Quarterly) | -0.0479 |
| Free Cash Flow to Equity (Quarterly) | -95.97M |
| Free Cash Flow to Firm (Quarterly) | -95.97M |
| Free Cash Flow Yield | -36.43% |